The accumulation of plasma advanced oxidation protein products (AOPPs) is prevalent in diverse disorders such as diabetes, metabolic syndromes, and chronic kidney disease. To study whether accumulated AOPPs have an important role in the progression of proteinuria and glomerulosclerosis, we chronically treated normal Sprague-Dawley rats with AOPP-modified rat serum albumin. Podocyte apoptosis was significantly increased coincident with the onset of albuminuria and preceded significant losses of glomerular podocytes. Increasing the amount of AOPPs in the media of conditionally immortalized podocytes rapidly triggered the production of intracellular superoxide by activation of NADPH oxidase and this, in turn, led to an upregulation of p53, Bax, caspase 3 activity, and apoptosis. Chronic inhibition of NADPH oxidase by apocynin prevented podocyte apoptosis, ameliorated podocyte depletion, and decreased albuminuria in AOPP-challenged rats. Our study demonstrates that accumulation of AOPPs promotes NADPH oxidase-dependent podocyte depletion by a p53-Bax apoptotic pathway both in vivo and in vitro.
Progression to renal parenchymal damage and end-stage renal disease, which seems to be largely independent of the initial insults, is the common pathway for chronic kidney disease (CKD) in both animals and humans. 1, 2 The key event of the pathway is the impairment of glomerular permeability to proteins, which permits excessive amounts of proteins to reach the lumen of the proximal tubule and contributes to renal interstitial injury by activating inflammatory and fibrogenic cascades. 3, 4 Glomerular visceral epithelial cell, or podocyte, is one of the major cell types in the glomerulus. The podocyte forms a critical part of the glomerular filtration barrier and functions to prevent urinary protein leakage and to maintain glomerular capillary loop integrity. 5 Podocyte depletion leads to areas of denuded glomerular basement membrane, culminating in proteinuria and development of glomerulosclerosis. 6 There is a growing body of literature showing that podocyte loss is related to increasing proteinuria and contributes to the progression of kidney disease in both diabetic and nondiabetic CKD. [7] [8] [9] [10] [11] [12] [13] Numerous factors have been implicated in the pathogenesis of podocyte injury and depletion: hyperglycemia, angiotensin II, reactive oxygen species, and transforming growth factor-b have been extensively characterized. [14] [15] [16] [17] [18] Recently, a family of oxidized protein compounds, termed 'advanced oxidation protein products' (AOPPs), has emerged as a novel class of renal pathogenic mediators. AOPPs are a class of dityrosine-containing protein products formed during oxidative stress and carried mainly by albumin in vivo. 19, 20 Accumulation of plasma AOPPs was first identified in patients who underwent dialysis 19 and was subsequently found in subjects with diabetes, 21, 22 metabolic syndrome, 23 and nondiabetic CKD. 20 Our recent studies have shown that chronic accumulation of plasma AOPPs significantly increases urinary protein excretion and accelerates glomerulosclerosis in a remnant kidney model. 24 An increase in the concentration of plasma AOPPs to the level that has been found in diabetic patients increases urinary excretion of albumin in both normal and streptozotocininduced diabetic rats. 24, 25 Consistent with these observations, data from a clinical study have shown that plasma AOPP level is a strong predictor for the prognosis of IgA nephropathy. 26 Although these observations suggest that AOPP accumulation has an important role in the progression of proteinuria and glomerulosclerosis, the underlying cellular and molecular mechanism(s) have not been clarified. It remains unknown whether AOPPs affect structure and function of the podocyte.
Two underlying mechanisms for podocyte loss are apoptosis and detachment. Apoptosis in glomerular cells has been demonstrated in animal models as well as in patients with chronic renal insufficiency, diabetes, and hypertension nephrosclerosis, [27] [28] [29] [30] in which the accumulation of AOPPs is implicated. Therefore, this study was designed to determine the contribution of AOPPs to podocyte loss. Our data show that the accumulation of AOPPs results in podocyte loss through the induction of apoptosis. AOPP-induced podocyte apoptosis is mainly mediated by the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-dependent superoxide generation, which activates the p53-Bcl-2-associated X (Bax)-caspase-3 proapoptotic pathway.
RESULTS

Chronic administration of AOPPs increased urinary albumin and 8-hydroxydeoxyguanosine excretion
To examine the renal pathogenic effects of AOPPs in vivo, normal Sprague-Dawley rats were randomly assigned to four groups and were treated with intravenous injection of AOPP-modified rat serum albumin (RSA) in the presence or absence of the NADPH oxidase inhibitor apocynin for 5-12 weeks. Plasma AOPP levels increased approximately onefold in AOPP-RSA-treated rats compared with that in vehicle-or RSA-treated controls (Table 1) . Chronic administration of AOPP-RSA, but not that of native RSA, significantly enhanced the renal deposition of AOPPs, increased urinary albumin excretion, and elevated the level of urinary 8-OHdG (8-hydroxydeoxyguanosine), a well-known biomarker of oxidative stress in vivo.
1 Intervention of apocynin significantly attenuated albuminuria and decreased urinary 8-OHdG level in AOPP-challenged rats. There was no significant difference in serum creatinine levels among the groups (Table 1) .
Podocyte apoptosis increased in AOPP-challenged rats and was ameliorated by treatment with apocynin
To determine whether AOPP accumulation induces podocyte apoptosis and to delineate the relationship between apoptosis and changes in podocyte number, we first quantified rates of podocyte apoptosis using double-immunofluorescence labeling, including Wilms's tumor-1 and terminal deoxyuridine nick-end labeling (TUNEL) assay. TUNEL-positive podocytes per glomerular cross-section were significantly increased in AOPP-treated rats from week 5 compared with age-matched control animals (vehicle-or RSA-treated rats) (Figure 1a and b) . Interestingly, apoptosis was also detectable in tubular epithelial cells, particularly in AOPP-treated rats (data not shown). Treatment of apocynin significantly prevented podocytes from AOPPinduced apoptosis (Figure 1a and b) , indicating that the apoptotic processes are dependent on the activation of NADPH oxidase.
To further confirm the in vivo proapoptotic effect of AOPPs on podocytes, we next identified and quantified podocytes in urine sediments. Podocytes in cytospin urine sediments were identified as either nucleated or multinucleated cells expressing podocalyxin, using an immunofluorescence microscope. As shown in Figure 1c , no urinary podocytes were detected in rats treated with vehicle or native RSA. The mean value of podocytes per milliliter urine among the animals treated with AOPP-RSA was 1.90 ± 1.14 (n ¼ 10) at week 5, with 68% of podocytes being apoptotic (indicated by positive TUNEL staining). Podocyturia in AOPP-treated rats appeared from week 3 and attained peak level at week 5 (data not shown). Intervention of apocynin significantly decreased podocyturia and urinary apoptotic podocytes at week 5 (Figure 1c -e).
Podocyte loss occurred in AOPP-challenged rats and was blocked by treatment with apocynin
To examine whether AOPP-induced podocyte apoptosis results in glomerular podocyte loss, we first examined the morphological changes in podocytes under electron microscopy. As shown in Figure 2 , specific indicators of podocyte injury, 31 including flattening of foot processes, local detachments of foot processes with loss of podocytes, leaving areas of denuded glomerular basement membrane, and loss of entire podocytes were found in AOPP-treated rats, which was largely ameliorated by treatment with apocynin ( Figure 2) . Similarly, podocyte number and podocyte density, as analyzed using stereological methods, were significantly reduced in AOPP-treated rats at week 12 compared with controls. Treatment of apocynin significantly ameliorated the AOPPinduced podocyte loss in the glomeruli (Table 2) . To determine whether podocyte apoptosis is associated with cellular regeneration, we examined the expression of ki-67 and proliferating cell nuclear antigen (PCNA) in kidney sections. Expression of ki-67 and PCNA was mainly located in tubular epithelial cells in AOPP-treated animals ( Figure 2 ). To clarify the underlying mechanism of AOPP-induced podocyte apoptosis, podocytes were preincubated for 1 h with the inhibitors of various enzymatic systems involved in reactive oxygen species generation, a broad spectrum inhibitor of protein kinase C (PKC) (Gö6983), and an intracellular superoxide (O 2 À ) scavenger (cytosolic Cu/Zn superoxide dismutase, c-SOD), respectively. The cells were then incubated with AOPP-MSA for 48 h. AOPP-MSAinduced podocyte apoptosis was significantly suppressed by the NADPH oxidase inhibitors, DPI (diphenyleneiodonium) and apocynin, the PKC inhibitor, Gö6983, and c-SOD, but not by the inhibitors of nitric oxidase synthase, cyclooxygenase, xanthine oxidase, and the inhibitors of mitochondrial respiratory chain complexes, suggesting that AOPP-triggered podocyte apoptosis is mainly mediated by PKC-NADPH oxidase-dependent O 2 À generation ( Figure 3d ).
AOPP challenge increased NADPH-dependent O 2 À generation in vitro and in vivo
To further confirm the presence of oxidative stress and the enzyme source of O 2 À in AOPP-challenged podocytes, oxidase activity in response to the addition of various substrates was examined in podocyte homogenates. As shown in Figure 4a , O 2 À production derived from NADPH was greater than that obtained from other potential substrates. NADPH-dependent O 2 À production was significantly enhanced in AOPP-treated podocytes compared with cells incubated with medium alone or native MSA (Figure 4b ). Furthermore, AOPP-triggered O 2 À generation was almost completely blocked by pretreating podocytes with Gö6983, DPI, apocynin, and c-SOD, but not by inhibitors of other potential enzymes, suggesting that AOPP-triggered O 2 À production in cultured podocytes is dependent on the activation of PKC-NADPH oxidase ( Figure 4b ).
Similarly, O 2 À production in renal cortex homogenates was significantly increased in AOPP-treated rats compared with that in controls, which could be almost completely inhibited by pretreatment of the homogenates with DPI or c-SOD (Figure 4c ).
AOPP challenge activated NADPH oxidase in vitro and in vivo
To further investigate the mechanisms underlying the induction of O 2 À by AOPPs, we examined the effect of AOPPs on the activity of NADPH oxidase. AOPP-MSA induced rapid phosphorylation of the cytoplasmic subunit p47 phox in cultured podocytes ( Figure 5a ). AOPP-induced p47 phox phosphorylation could be blocked by pretreatment of podocytes with a PKC inhibitor, Gö6983 (Figure 5a ).
To examine the interaction of p47 phox with the membrane subunits, we immunoprecipitated p22 phox , Nox 2, and Nox 4 with the specific antibodies, and then probed for the coexistence of p47 phox . As shown in Figure 5b , the amount of p47 phox -p22 phox complex formation rapidly increased in AOPP-stimulated podocytes. At 15 min after AOPP challenge, p47 phox membrane translocation was apparent ( Figure 5c ). AOPPs also promoted the association of p47 phox with Nox 2 and Nox 4 ( Figure 5d ).
The increased expression of NADPH oxidase subunits might be necessary for its sustained activation. To examine 
c-SOD (100 U/ml) Gö6983 (10 μmol/l) the effect of AOPPs on the expression of the oxidase subunits, podocytes were incubated with AOPP-MSA for 1-12 h. Compared with cells incubated with native MSA, podocytes treated with AOPP-MSA showed significantly increased expression of p47 phox , Nox 2, and Nox 4, after 3 h of stimulation (Figure 5e ). Similarly, renal cortex homogenates from the AOPP-treated rats showed a significantly upregulated expression of p47 phox and Nox homologs compared with controls (Figure 5f ).
AOPP-induced apoptosis was associated with increased p53 and Bax protein synthesis and caspase-3 activity Upregulation of p53 has been reported to mediate apoptosis through Bax protein expression in response to a number of stress signals. 2, 32 To examine the potential mediators of AOPP-induced apoptosis, we analyzed the abundance of p53 and Bcl-2 family proteins (Bax and Bcl-2) and that of caspase-3 by western blot analysis. AOPP challenge increased p53 expression in cultured podocytes from 2 h. Proapoptotic Bax expression was increased from 6 h (Figure 6a ), followed by a decrease in procaspase-3 levels and increase in cleaved caspase-3 at 6-48 h of AOPPs treatment ( Figure  6b ). Levels of intact 113-kDa PARP (poly (adenosine diphosphate-ribose) polymerase), a substrate of activated caspases, were decreased from 12 h, coincident with the appearance of 85-kDa PARP cleavage products (Figure 6b ). These data suggest that AOPP-induced apoptosis is associated with increase activity of the p53-Bax-caspase-3 pathway. Enhanced expression of p53 and Bax protein and activation of caspase-3, could be blocked by the inhibitors of PKC and NADPH oxidase, suggesting that AOPP-induced activation of proapoptotic molecules is mainly mediated by PKC-NADPH oxidase-dependent O 2 À generation ( Figure 6c ). Consistent with the in vitro observation, western blot analysis of the renal cortex homogenates showed upregulation of p53, Bax, and caspase-3 in AOPPtreated rats (Figure 6d ).
DISCUSSION
Increased recognition of AOPPs, as a class of potential renal pathogenic mediators and the multiple means by which they form in diverse disorders, has highlighted the importance of determining mechanisms by which AOPPs might induce or promote the progression of glomerulopathy. This study provided in vivo and in vitro evidence showing that the accumulation of AOPPs triggers podocyte apoptosis and results in podocyte depletion through NADPH oxidasedependent O 2 À generation. AOPP-albumin, but not native albumin, altered the life span of the podocyte, suggesting that the triggering effect is due to AOPPs and is not a property of albumin or other contaminants. To the best of our knowledge, this is the first study showing the role of AOPPs in the pathogenesis of podocyte depletion.
Podocyte depletion has been proposed as a hallmark of primary and secondary forms of glomerulosclerosis for many years. 6, 33 The extent of podocyte depletion is now considered a central problem in the progression of both diabetic and nondiabetic nephropathy. 10, 12, 34, 35 Although clinical and animal studies clearly demonstrate the phenomenon of podocyte depletion in various glomerular diseases, the mechanism(s) underlying podocyte loss have not been completely understood. Podocyte apoptosis has been shown to be a glomerular phenotype that coincides with the onset of albuminuria and is associated with progressive podocyte depletion.
14, 15 Several factors have been suggested to induce podocyte apoptosis; hyperglycemia, transforming growth factor-b, and angiotensin II have been extensively characterized. [14] [15] [16] [17] In this study, we identified AOPP accumulation as a new candidate mechanism for podocyte apoptosis and podocyte depletion. As we have reported previously, 24, 36 chronic administration of AOPP-albumin in normal rats increased the plasma concentration of AOPPs to the level that has been found in diabetic plasma and increased AOPP deposition in the renal tissue. In this model, podocyte apoptosis developed at week 5 and coincided with the onset of albuminuria. The in vitro study also showed that both AOPP-MSA and AOPP fraction isolated from uremic patients triggered podocyte apoptosis in a dose-and time-dependent manner. It is noteworthy that, apoptosis of tubular epithelial cells was also increased in AOPP-treated rats, suggesting that epithelial cells might be selectively susceptible to AOPPinduced apoptosis. Interestingly, a recent in vitro study has also shown that AOPP challenge promotes renal tubular cells injury through a CD36-dependent pathway. 37 Our very recent finding shows that AOPPs also target mesangial cells, 38 suggesting that at least some of the renal pathogenic effects of AOPPs might be mediated by the mechanism independent of podocyte lesion.
Importantly, this study shows that AOPP-triggered apoptosis is sufficient to induce podocyte loss in vivo. The following lines of evidence support this conclusion. First, podocyte apoptosis coincided with the onset of podocyturia and 68% of urinary podocytes underwent apoptosis. Consistent with this finding, a previous study indicated that podocyturia is associated with podocyte loss and progression of IgA nephropathy, a disorder with the prevalence of AOPP accumulation. 12, 26 Second, morphological observation of the AOPP-challenged kidney showed structural changes in response to loss of podocytes and denudation of glomerular basement membrane. Third, reduction in podocyte number and decreased glomerular podocyte density, as judged by the unbiased stereological methods, further confirmed the loss of podocytes in AOPP-treated animals. A progressive depletion of podocytes results in denuded glomerular basement membrane areas and tuft adhesions that has been considered as initial lesions of irreversible glomerular damage. 39 Furthermore, the inability to undergo cell regeneration after podocyte damage may also result in glomerulosclerosis. 40 Taken together, our finding suggests that accumulation of AOPPs might be involved in the initiation or progression of CKD by promoting podocyte depletion. Supporting the notion, our previous studies have shown that chronic accumulation of AOPPs promotes renal damage in a diabetic model and accelerates glomerulosclerosis in the remnant kidney. 12, 25 In this study, we also showed that AOPP-induced podocyte apoptosis and depletion are mainly mediated by NADPH oxidase-dependent superoxide generation. Human and rodent podocytes express the components of NADPH oxidase including p47 phox , p22 phox , and Nox homologs. NADPH oxidase represents the major source of superoxide . Podocytes were treated as described above. IP was performed using an a-p22 phox , and IB was conducted using an a-p47 generation in both cultured podocytes and in the renal cortex. 39, 41 In this study, we first showed that AOPP challenge induced overproduction of O 2 À in cultured podocytes and in the in renal cortex. AOPP-induced O 2 À production was NADPH dependent and could be blocked by the inhibitors of NADPH oxidase. Next, we examined the activity of NADPH oxidase in AOPP-challenged podocytes. Exposure of podocytes to AOPPs induced rapid phosphorylation of the cytoplasmic subunit p47 phox and its membrane translocation; this was followed by increased interaction of p47 phox with the membrane subunits p22 phox , Nox 2, and Nox 4, confirming the activation of total oxidase in AOPP-triggered podocytes. Furthermore, we showed that expression of the key subunits of NADPH oxidase, including that of p47 phox , p22 phox , Nox 2, and Nox 4, was upregulated in cultured podocytes after 3 h of exposure to AOPPs. Overexpression of these NADPH oxidase subunits was also found in the renal cortex of rats treated with AOPPs. Finally, we provided data showing that AOPPinduced apoptosis could be largely blocked by pretreating podocytes with the NADPH oxidase inhibitors and the intracellular O 2 À scavenger in vitro, or by the intervention of apocynin in vivo. Oxidant-dependent DNA damage in podocytes has also been found in puromycin aminonucleoside-treated rats. 18 These data suggest that NADPH oxidase-dependent O 2 À generation constitutes a major pathway resulting in AOPP-induced podocyte apoptosis. This was validated in principle in vivo after the chronic inhibition of NADPH oxidase in diabetic models. 25, 42, 43 The pathophysiological relevance of NADPH oxidase activation in the induction of renal oxidative stress is further supported by the observation of increased urinary 8-OHdG.
Activation of NADPH oxidase occurs through multiple signaling pathways; 44 however, several studies have demonstrated a critical role of PKC. 1, 45, 46 In this study, a broad spectrum inhibitor of PKC (Gö6983) inhibited AOPPinduced NADPH oxidase activation and O 2 À production, and blocked subsequent apoptosis in cultured podocytes, suggesting that PKC may be located upstream of oxidase activation in the signaling pathway that leads to AOPPinduced O 2 À production. Both podocyte growth and apoptosis are complexly regulated by the Bcl-2 family, including both proapoptotic molecules (such as Bax) and antiapoptotic molecules (such as Bcl-2). These molecules are regulators of caspases, which serve as the terminal effectors molecules in many types of apoptosis. 47 In this study, we found that AOPP challenge increased p53 accumulation in podocytes. Furthermore, the expression of proapoptotic molecule Bax protein and the activity of effector caspase-3 were significantly increased by treatment with AOPPs. As p53 has been reported to mediate programmed cell death through Bax protein expression in response to a number of stress signals, 2, 32 AOPP challenge might induce apoptosis in the podocyte through p53-dependent Bax expression. It is noteworthy that the kinetic profile in this study showed significant induction of O 2 À content as early as 0.5 h; this was followed by the upregulation of p53 after 2 h of exposure and increased expression of Bax after 6 h of incubation. Moreover, the AOPP-triggered p53-Bax-caspase pathway could be almost completely blocked by c-SOD and NADPH oxidase inhibitor, suggesting that the proapoptotic pathway is activated by superoxide produced by NADPH oxidase activation.
In summary, we conclude that accumulation of AOPPs promotes podocyte depletion by the induction of podocyte apoptosis, which is mainly mediated by NADPH oxidasedependent O 2 À generation. Given that AOPP accumulation is prevalent in diverse pathophysiological conditions such as diabetes, metabolic syndrome, and CKD, this finding might be highly significant because it might be an important step toward understanding the renal pathogenic effects of AOPPs and may provide new targets for the prevention of progressive glomerulosclerosis seen in these disorders.
MATERIALS AND METHODS AOPP-albumin preparation AOPP-RSA and AOPP-MSA were prepared in vitro by incubation of RSA or MSA (Sigma Chemical, St Louis, MO, USA) with 200 mmol/l of hypochlorous acid (Fluke, Buchs, Switzerland) in the absence of free amino acid/carbohydrates/lipids to exclude the formation of advanced glycation end products-like structures. 19, 24 Prepared samples were dialyzed against phosphate-buffered saline to remove free hypochlorous acid. AOPP fraction formed in vivo was isolated from the serum of patients with uremia using HiPrep 16/60 Sephacryl S-300HR column (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) as described previously. 48 The concentration of AOPP fraction in patients' serum was B200 mg/ml. 48 All samples were passed through a DetoxiGel column (Pierce, Rockford, IL, USA) to remove contaminated endotoxin. The endotoxin levels in the preparations were tested using the Amebocyte Lysate Kit (Sigma Chemical) and were found to be o0.025 EU/ml. AOPP content in the preparation, as determined by the absorbance of the reaction mixture of the samples and acetic acid, 19, 24 was 56.4 ± 4.3 nmol/mg protein in AOPP-RSA, 73.6 ± 8.4 nmol/mg protein in AOPP-MSA, 0.30±0.03 nmol/mg protein in native RSA, and 0.25 ± 0.02 nmol/mg protein in native MSA. The components of advanced glycation end products were undetectable in the prepared samples. [49] [50] [51] Cell culture Murine podocytes were generously provided by Professor Peter Mundel (Sinai School of Medicine, New York, NY, USA) and cultured as described previously. 52 Undifferentiated podocytes were grown in RPMI 1640 containing 10% fetal bovine serum, penicillin (100 U/ml), streptomycin (100 mg/ml), sodium pyruvate (1 mmol/l), HEPES buffer (10 mmol/l), and sodium bicarbonate (0.075%) (all obtained from Sigma Chemical). To passage the cells, podocytes were grown under 'growth-permissive' conditions, which involved growing cells at 33 1C in the presence of interferon-g (50 U/ml, Sigma Chemical). For podocytes to acquire a differentiated phenotype, cells were grown under 'restrictive conditions' at 37 1C in the absence of interferon-g for more than 12 days. Experiments were carried out using passages 10-18, growth-restricted, conditionally immortalized podocytes.
Animal studies
Male Sprague-Dawley rats (initial weight, 180-200 g, Southern Medical University Animal Experiment Center, Guangzhou, China) were housed in a standard environment with free access to water and diet. The rats were randomly assigned to four groups (n ¼ 10 in each group) and received daily intravenous injection of vehicle (phosphate-buffered saline, pH 7.4), native RSA (100 mg/kg per day), AOPP-RSA (100 mg/ kg per day), and AOPP-RSA (100 mg/kg per day) with intragastric administration of apocynin (Sigma Chemical, 100 mg/kg per day), separately. 50 The dosages of AOPPs and the internal injection were based on our preliminary studies, in which plasma AOPP levels increase approximately onefold of the normal concentration in rats (the level that has been found in patients with diabetes). 24, 25 The rats were killed at the end of weeks 5 and 12. Their kidneys were collected after perfusion with 50 ml of ice-cold normal saline. AOPP levels in the plasma and renal cortex homogenate were measured as described above.
Assessment of podocyte apoptosis
AV-labeled cells in cultured podocytes. Determination of AV-labeled apoptotic cells was performed as described previously. 53 Cell suspension was incubated with either fluorescein isothiocyanate (FITC)-conjugated AV alone, propidium iodide (PI) alone, or a combination of both according to the manufacturer's instructions (KeyGen, Nanking, China). Cells were analyzed using a flow cytometer (BD FACSCalibur System, Franklin Lakes, NJ, USA), with excitation at 488 nm and emission at 525 nm (for AV-labeled cells) and 620 nm (for PI-labeled cells). Single labeling was used to gate and control for bleed through. Cell population was characterized on the basis of whether it was labeled with neither AV nor PI (viable), AV alone (apoptotic), PI alone (necrotic), or both AV and PI (late apoptotic).
TUNEL assay in cultured podocytes. DNA strand breaks in cultured podocytes were identified using TUNEL as described previously. 49 The cells were fixed in 4% paraformaldehydrate followed by methanol. After washing, cells were incubated in TDT buffer containing the TdT enzyme and FITC-conjugated dUTP according to the manufacturer's protocol (KeyGen). Morphological changes in cells undergoing apoptosis were detected simultaneously by counterstaining them with Hoechst 33258 (KeyGen, Nanking, China). The slides were examined by fluorescent microscopy (Leica TCS SP2 AOBS, Leica Microsystems, Cambridge, UK).
Analysis of podocyte apoptosis in renal tissue. Apoptotic cells were detected on frozen kidney section using FITC-labeled in situ Apoptosis Detection Kit (KeyGen, Wuhan, China). For identification of the apoptotic podocyte, tissue sections were costained with anti-Wilms's tumor-1 antibody (red) and TUNEL (green). The cells double labeled by Wilms's tumor-1 and TUNEL were counted as apoptotic podocytes.
Identification of apoptotic podocytes in urine. Rat sterile urine was collected by bladder puncture as described previously. 54 Resuspended cell pellets were centrifuged onto polylysine-coated slides, fixed with 3% paraformaldehyde, and then permeabilized with Triton X-100. After blocking with 1% bovine serum albumin, the slides were incubated with a goat anti-rat podocalyxin antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and then with the secondary antibody TRITC-labeled donkey anti-goat IgG (Santa Cruz Biotechnology). The sediments were counterstained with Hoechst nuclear stain to distinguish whole cells from cell fragments. TUNEL staining for apoptosis was performed on the specimens using a standard FITC incorporation kit (KeyGen) according to the package instructions. The slides were examined using a fluorescence microscope (BX51, Olympus, Tokyo, Japan) at 590 nm for podocalyxin, 488 nm for TUNEL, and 460 nm for Hoechst. Nucleated, podocalyxin-positive cells were considered to be detached podocytes and those with a positive staining of FITC were regarded as apoptotic podocytes. Urinary podocyte number was quantified in a blinded manner and was shown as cells per milliliter urine.
Expression of apoptosis-related molecules. To measure the protein expression of apoptosis-related molecules, cultured cells were lysed and the frozen renal cortex was processed for protein extraction as described previously. 55 The protein samples were subjected to 8-12% SDS-PAGE before being transferred into PVDF (polyvinylidene fluoride) membranes (NEN Life Science Products, Boston, MA, USA). Western blotting was performed as described elsewhere 56 using the following primary antibodies: anti-p53 mAb (Oncogene Research Products, San Diego, CA, USA), anti-Bax mAb (Santa Cruz Biotechnology), polyclonal rabbit anti-caspase-3 (Cell Signaling Technology, Beverly, MA, USA), anti-Bcl-2 mAb (Santa Cruz Biotechnology), and anti-PARP mAb (Cell Signaling Technology). Bound primary antibodies were detected with horseradish peroxidase (HRP)-labeled anti-mouse or anti-rabbit secondary antibodies, and visualized using enhanced chemiluminescence reagents (Pierce Chemical, Bockford, IN, USA).
Morphological observation
Renal cortex or podocyte sediment was processed through a primary and a secondary fixation, acetone dehydration, and then EponSpurr's resin infiltration as described previously. 57 Samples were rocked overnight and then embedded and polymerized at 60 1C for 24 h. Thin sections (80 nm) were collected and stained with uranyl acetate and lead citrate. A transmission electron microscope (Hitachi, Tokyo, Japan) was used to observe the samples.
Immunohistochemical analysis of ki-67 and PCNA The expression of ki-67 and PCNA in the kidney section was determined as described previously. 58, 59 The sections of paraffinembedded tissues were rehydrated in phosphate-buffered saline and subjected to microwave heating. The sections were stained by monoclonal anti-ki-67 antibody (Dako, Carpinteria, CA, USA) or monoclonal mouse anti-rat PCNA antibody (Boster, Wuhan, China) and then detected using the Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA).
Determination of podocyte number and density in the glomerulus Sections of 1-mm thickness from the Spurrs blocks were used for the studies. After facing the block, the first intact section was saved and numbered 0. At least 200 serial sections were then cut from each kidney. Every 19th and 20th section was saved together on a slide so that at least 10 pairs of sections were available for analysis from each rat. All sections were stained with 1% toluidine blue. The first five glomeruli not present in section 0, but appearing and disappearing in subsequent sections, were mapped to a location within the sections and were numbered 1-5. An Olympus BX51 microscope, fitted with a digital camera and DP Controller software (Olympus, Tokyo, Japan)
